Dofetilida [Inn-Spanish]
Brand names,
Dofetilida [Inn-Spanish]
Analogs
Dofetilida [Inn-Spanish]
Brand Names Mixture
Dofetilida [Inn-Spanish]
Chemical_Formula
C19H27N3O5S2
Dofetilida [Inn-Spanish]
RX_link
http://www.rxlist.com/cgi/generic2/dofetilide.htm
Dofetilida [Inn-Spanish]
fda sheet
Dofetilida [Inn-Spanish]
msds (material safety sheet)
Dofetilida [Inn-Spanish]
Synthesis Reference
No information avaliable
Dofetilida [Inn-Spanish]
Molecular Weight
441.567 g/mol
Dofetilida [Inn-Spanish]
Melting Point
No information avaliable
Dofetilida [Inn-Spanish]
H2O Solubility
No information avaliable
Dofetilida [Inn-Spanish]
State
Solid
Dofetilida [Inn-Spanish]
LogP
4.574
Dofetilida [Inn-Spanish]
Dosage Forms
Capsule
Dofetilida [Inn-Spanish]
Indication
For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Dofetilida [Inn-Spanish]
Pharmacology
Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.
Dofetilida [Inn-Spanish]
Absorption
>90%
Dofetilida [Inn-Spanish]
side effects and Toxicity
No information avaliable
Dofetilida [Inn-Spanish]
Patient Information
No information avaliable
Dofetilida [Inn-Spanish]
Organisms Affected
Humans and other mammals